Interferon-alpha administration enhances CD8+ T cell activation in HIV infection

Maura Manion, Benigno Rodriguez, Kathleen Medvik, Gareth Hardy, Clifford V. Harding, Robert T. Schooley, Richard B Pollard, David Asmuth, Robert Murphy, Edward Barker, Kirsten E. Brady, Alan Landay, Nick Funderburg, Scott F. Sieg, Michael M. Lederman

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: Type I interferons play important roles in innate immune defense. In HIV infection, type I interferons may delay disease progression by inhibiting viral replication while at the same time accelerating disease progression by contributing to chronic immune activation. Methods: To investigate the effects of type I interferons in HIV-infection, we obtained cryopreserved peripheral blood mononuclear cell samples from 10 subjects who participated in AIDS Clinical Trials Group Study 5192, a trial investigating the activity of systemic administration of IFNα for twelve weeks to patients with untreated HIV infection. Using flow cytometry, we examined changes in cell cycle status and expression of activation antigens by circulating T cells and their maturation subsets before, during and after IFNα treatment. Results: The proportion of CD38+HLA-DR+CD8+ T cells increased from a mean of 11.7% at baseline to 24.1% after twelve weeks of interferon treatment (p = 0.006). These frequencies dropped to an average of 20.1% six weeks after the end of treatment. In contrast to CD8+ T cells, the frequencies of activated CD4+ T cells did not change with administration of type I interferon (mean percentage of CD38+DR+ cells = 2.62% at baseline and 2.17% after 12 weeks of interferon therapy). As plasma HIV levels fell with interferon therapy, this was correlated with a "paradoxical" increase in CD8+ T cell activation (p<0.001). Conclusion: Administration of type I interferon increased expression of the activation markers CD38 and HLA DR on CD8+ T cells but not on CD4+ T cells of HIV+ persons. These observations suggest that type I interferons may contribute to the high levels of CD8+ T cell activation that occur during HIV infection.

Original languageEnglish (US)
Article numbere30306
JournalPLoS One
Volume7
Issue number1
DOIs
StatePublished - Jan 24 2012

Fingerprint

interferon-alpha
T-cells
HIV infections
Interferon Type I
interferons
Interferon-alpha
HIV Infections
T-lymphocytes
Chemical activation
T-Lymphocytes
Interferons
HLA-DR Antigens
Disease Progression
disease course
CD27 Antigens
HIV
Therapeutics
Flow cytometry
therapeutics
Blood Cells

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Manion, M., Rodriguez, B., Medvik, K., Hardy, G., Harding, C. V., Schooley, R. T., ... Lederman, M. M. (2012). Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One, 7(1), [e30306]. https://doi.org/10.1371/journal.pone.0030306

Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. / Manion, Maura; Rodriguez, Benigno; Medvik, Kathleen; Hardy, Gareth; Harding, Clifford V.; Schooley, Robert T.; Pollard, Richard B; Asmuth, David; Murphy, Robert; Barker, Edward; Brady, Kirsten E.; Landay, Alan; Funderburg, Nick; Sieg, Scott F.; Lederman, Michael M.

In: PLoS One, Vol. 7, No. 1, e30306, 24.01.2012.

Research output: Contribution to journalArticle

Manion, M, Rodriguez, B, Medvik, K, Hardy, G, Harding, CV, Schooley, RT, Pollard, RB, Asmuth, D, Murphy, R, Barker, E, Brady, KE, Landay, A, Funderburg, N, Sieg, SF & Lederman, MM 2012, 'Interferon-alpha administration enhances CD8+ T cell activation in HIV infection', PLoS One, vol. 7, no. 1, e30306. https://doi.org/10.1371/journal.pone.0030306
Manion M, Rodriguez B, Medvik K, Hardy G, Harding CV, Schooley RT et al. Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One. 2012 Jan 24;7(1). e30306. https://doi.org/10.1371/journal.pone.0030306
Manion, Maura ; Rodriguez, Benigno ; Medvik, Kathleen ; Hardy, Gareth ; Harding, Clifford V. ; Schooley, Robert T. ; Pollard, Richard B ; Asmuth, David ; Murphy, Robert ; Barker, Edward ; Brady, Kirsten E. ; Landay, Alan ; Funderburg, Nick ; Sieg, Scott F. ; Lederman, Michael M. / Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. In: PLoS One. 2012 ; Vol. 7, No. 1.
@article{630d5f77110144408d2ff94e46b47896,
title = "Interferon-alpha administration enhances CD8+ T cell activation in HIV infection",
abstract = "Background: Type I interferons play important roles in innate immune defense. In HIV infection, type I interferons may delay disease progression by inhibiting viral replication while at the same time accelerating disease progression by contributing to chronic immune activation. Methods: To investigate the effects of type I interferons in HIV-infection, we obtained cryopreserved peripheral blood mononuclear cell samples from 10 subjects who participated in AIDS Clinical Trials Group Study 5192, a trial investigating the activity of systemic administration of IFNα for twelve weeks to patients with untreated HIV infection. Using flow cytometry, we examined changes in cell cycle status and expression of activation antigens by circulating T cells and their maturation subsets before, during and after IFNα treatment. Results: The proportion of CD38+HLA-DR+CD8+ T cells increased from a mean of 11.7{\%} at baseline to 24.1{\%} after twelve weeks of interferon treatment (p = 0.006). These frequencies dropped to an average of 20.1{\%} six weeks after the end of treatment. In contrast to CD8+ T cells, the frequencies of activated CD4+ T cells did not change with administration of type I interferon (mean percentage of CD38+DR+ cells = 2.62{\%} at baseline and 2.17{\%} after 12 weeks of interferon therapy). As plasma HIV levels fell with interferon therapy, this was correlated with a {"}paradoxical{"} increase in CD8+ T cell activation (p<0.001). Conclusion: Administration of type I interferon increased expression of the activation markers CD38 and HLA DR on CD8+ T cells but not on CD4+ T cells of HIV+ persons. These observations suggest that type I interferons may contribute to the high levels of CD8+ T cell activation that occur during HIV infection.",
author = "Maura Manion and Benigno Rodriguez and Kathleen Medvik and Gareth Hardy and Harding, {Clifford V.} and Schooley, {Robert T.} and Pollard, {Richard B} and David Asmuth and Robert Murphy and Edward Barker and Brady, {Kirsten E.} and Alan Landay and Nick Funderburg and Sieg, {Scott F.} and Lederman, {Michael M.}",
year = "2012",
month = "1",
day = "24",
doi = "10.1371/journal.pone.0030306",
language = "English (US)",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - Interferon-alpha administration enhances CD8+ T cell activation in HIV infection

AU - Manion, Maura

AU - Rodriguez, Benigno

AU - Medvik, Kathleen

AU - Hardy, Gareth

AU - Harding, Clifford V.

AU - Schooley, Robert T.

AU - Pollard, Richard B

AU - Asmuth, David

AU - Murphy, Robert

AU - Barker, Edward

AU - Brady, Kirsten E.

AU - Landay, Alan

AU - Funderburg, Nick

AU - Sieg, Scott F.

AU - Lederman, Michael M.

PY - 2012/1/24

Y1 - 2012/1/24

N2 - Background: Type I interferons play important roles in innate immune defense. In HIV infection, type I interferons may delay disease progression by inhibiting viral replication while at the same time accelerating disease progression by contributing to chronic immune activation. Methods: To investigate the effects of type I interferons in HIV-infection, we obtained cryopreserved peripheral blood mononuclear cell samples from 10 subjects who participated in AIDS Clinical Trials Group Study 5192, a trial investigating the activity of systemic administration of IFNα for twelve weeks to patients with untreated HIV infection. Using flow cytometry, we examined changes in cell cycle status and expression of activation antigens by circulating T cells and their maturation subsets before, during and after IFNα treatment. Results: The proportion of CD38+HLA-DR+CD8+ T cells increased from a mean of 11.7% at baseline to 24.1% after twelve weeks of interferon treatment (p = 0.006). These frequencies dropped to an average of 20.1% six weeks after the end of treatment. In contrast to CD8+ T cells, the frequencies of activated CD4+ T cells did not change with administration of type I interferon (mean percentage of CD38+DR+ cells = 2.62% at baseline and 2.17% after 12 weeks of interferon therapy). As plasma HIV levels fell with interferon therapy, this was correlated with a "paradoxical" increase in CD8+ T cell activation (p<0.001). Conclusion: Administration of type I interferon increased expression of the activation markers CD38 and HLA DR on CD8+ T cells but not on CD4+ T cells of HIV+ persons. These observations suggest that type I interferons may contribute to the high levels of CD8+ T cell activation that occur during HIV infection.

AB - Background: Type I interferons play important roles in innate immune defense. In HIV infection, type I interferons may delay disease progression by inhibiting viral replication while at the same time accelerating disease progression by contributing to chronic immune activation. Methods: To investigate the effects of type I interferons in HIV-infection, we obtained cryopreserved peripheral blood mononuclear cell samples from 10 subjects who participated in AIDS Clinical Trials Group Study 5192, a trial investigating the activity of systemic administration of IFNα for twelve weeks to patients with untreated HIV infection. Using flow cytometry, we examined changes in cell cycle status and expression of activation antigens by circulating T cells and their maturation subsets before, during and after IFNα treatment. Results: The proportion of CD38+HLA-DR+CD8+ T cells increased from a mean of 11.7% at baseline to 24.1% after twelve weeks of interferon treatment (p = 0.006). These frequencies dropped to an average of 20.1% six weeks after the end of treatment. In contrast to CD8+ T cells, the frequencies of activated CD4+ T cells did not change with administration of type I interferon (mean percentage of CD38+DR+ cells = 2.62% at baseline and 2.17% after 12 weeks of interferon therapy). As plasma HIV levels fell with interferon therapy, this was correlated with a "paradoxical" increase in CD8+ T cell activation (p<0.001). Conclusion: Administration of type I interferon increased expression of the activation markers CD38 and HLA DR on CD8+ T cells but not on CD4+ T cells of HIV+ persons. These observations suggest that type I interferons may contribute to the high levels of CD8+ T cell activation that occur during HIV infection.

UR - http://www.scopus.com/inward/record.url?scp=84856183595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856183595&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0030306

DO - 10.1371/journal.pone.0030306

M3 - Article

C2 - 22291932

AN - SCOPUS:84856183595

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e30306

ER -